Evidence map›Paper›PMID 40401088›Full record

ArticleFrontiers in neural circuits2025

Long-term self-reported symptoms and psychophysical tests in COVID-19 subjects experiencing persistent olfactory dysfunction: a 4-year follow-up study.

Tommaso Saccardo, Giuseppe Roccuzzo, Alessandro Fontana, Sonny Zampollo, Bruno Scarpa, Piero Nicolai, Alfonso Luca Pendolino, Carla Mucignat, Rosario Marchese-Ragona, Giancarlo Ottaviano

Abstract read
In one paragraph

Article in Frontiers in neural circuits, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tommaso SaccardoOtolaryngology Section, Department of Neurosciences, University of Padova, Padova, Italy.
Giuseppe RoccuzzoOtolaryngology Section, Department of Neurosciences, University of Padova, Padova, Italy.
Alessandro FontanaOtolaryngology Section, Department of Neurosciences, University of Padova, Padova, Italy.
Sonny ZampolloOtolaryngology Section, Department of Neurosciences, University of Padova, Padova, Italy.
Bruno ScarpaDepartment of Statistical Sciences, University of Padova, Padova, Italy.
Piero NicolaiOtolaryngology Section, Department of Neurosciences, University of Padova, Padova, Italy.
Alfonso Luca PendolinoEar Institute, University College London, London, United Kingdom.
Carla MucignatDepartment of Molecular Medicine, University of Padova, Padova, Italy.
Rosario Marchese-RagonaOtolaryngology Section, Department of Neurosciences, University of Padova, Padova, Italy.
Giancarlo OttavianoOtolaryngology Section, Department of Neurosciences, University of Padova, Padova, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Since the onset of the COVID-19 pandemic, chemosensory dysfunction (CD), including olfactory and taste quantitative dysfunction (OD/TD), has emerged as a prevalent and early symptom in SARS-CoV-2-infected subjects. This study explores the prevalence, duration, and recovery trajectory of COVID-19-related olfactory dysfunction (C19OD), with a specific focus on the four-year follow-up. Methods: Using a combination of psychophysical tests (Sniffin' sticks) and patient-reported outcome measures (sVAS and tVAS), 83 participants were prospectively evaluated for OD and parosmia. Factors influencing long-term olfactory recovery were analysed. Results: Baseline assessments revealed OD in 56.6% of patients, with progressive improvement observed over 4 years. At the four-year follow-up, 92.3% of patients recovered their olfaction while the remaining still reported hyposmia. Younger age and olfactory training were found to be favourable prognostic factors. Conclusion: Our findings show that, despite most individuals with C19OD recover olfaction within the first year, a subset of them continue to experience prolonged CD, demonstrating a slow, constant and meaningful improvement over years. This prolonged recovery period highlights the complexity of SARS-CoV-2's impact on olfactory function and highlights the need of further research on CD pathophysiology with the aim to improve therapeutic approaches to C19OD.

Indexed as

COVID-19Olfaction DisordersAdultAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedPatient Reported Outcome MeasuresProspective StudiesPsychophysicsSelf ReportSmellCOVID-19olfactory recoveryparosmiasmell lossSniffin’ stick test

Identifiers

PMID40401088
PMCPMC12092350

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.